ProShares Ultra NASDAQ Biotechnology
27 hedge funds and large institutions have $19.7M invested in ProShares Ultra NASDAQ Biotechnology in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
25% less call options, than puts
Call options by funds: $8.44M | Put options by funds: $11.2M
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Holders
27
Holding in Top 10
–
Calls
$8.44M
Puts
$11.2M
Top Buyers
| 1 | +$8.53M | |
| 2 | +$2.6M | |
| 3 | +$1.32M | |
| 4 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
+$464K |
| 5 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
+$294K |
Top Sellers
| 1 | -$1.79M | |
| 2 | -$694K | |
| 3 | -$489K | |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$261K |
| 5 |
Morgan Stanley
New York
|
-$142K |